Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAccsys Tech Regulatory News (AXS)

Share Price Information for Accsys Tech (AXS)

Share Price is delayed by 15 minutes
Get Live Data
77.00    0.00 (0.00%)
Bid:
76.00
Ask:
77.80
Spread: 1.80 (2.368%)
Market Cap: £187.07m
AXS Live PriceLast checked at - London Stock Exchange

Intraday Accsys Tech Share Chart

Replacement: Interim Management Statement

12 Feb 2014 07:47

RNS Number : 8778Z
Accsys Technologies PLC
12 February 2014
 



 

AIM: AXS

NYSE Euronext Amsterdam: AXS

12 February 2014

 

The following amendment has been made to the 'Interim Management Statement' announcement released on 12/0214 at 07:00 under RNS No 8241Z.

 

We have removed the word "Draft" from the title.

 

All other details remain unchanged.

 

The full amended text is shown below.

 

ACCSYS TECHNOLOGIES PLC

("Accsys" or the "Company")

 

Interim Management Statement

 

Accsys, the environmental science and technology company whose primary focus is on the production and technology licensing of Accoya® wood and Tricoya® wood elements, today issues its Interim Management Statement. Key highlights include:

 

· Strong performance, in line with market expectations, with total revenue increasing by 71% to €23.0m for the nine months ended December 2013 (2012: €13.4m);

· Continuing growth in demand with Accoya® wood revenue increasing by 74% to €20.2m for the nine months ended December 2013 (2012: €11.6m). Excluding sales to Medite, Accoya® revenue increased by 58% to €18.4m (2012: €11.6m);

· Total Accoya® volume sold in the nine months to December 2013 increased by 89% compared to the same period in the previous year;

· Arnhem plant profitability continues to improve and further price increases are being implemented;

· Accoya licence agreement with Solvay has been formally approved;

· Significant milestone met with Accsys delivering the Process Design Package to Solvay;

· Total of 57 Accoya® distributor and agency agreements now in place covering most of Europe, Australia, Canada, Chile, China, India, Mexico, Morocco, New Zealand, parts of South-East Asia and the USA; and

· Strong balance sheet with cash balance of €14.4m at 31 December 2013 (September 2013: €16.9m).

Trading update

During the period Accsys has made significant progress towards delivering on objectives:

Accoya Licence Agreement with Solvay Formally Approved

In December last year Accsys announced that its Accoya® licence agreement ('the licence agreement') with Belgian chemical group Solvay was approved by both parties and is fully effective, resulting in a new level of cooperation between the two companies.

The licence agreement grants Solvay exclusive rights for a minimum of 15 year period, renewable at agreed terms, to produce and to sell Accoya® within the Council of Europe from this initial plant. The licenced territory includes 47 states in the Council of Europe, but excluding Belgium, Ireland, Luxembourg, the Netherlands and the United Kingdom which are reserved to Accsys. The licence agreement also grants Solvay the option to build additional Accoya® production plants in Europe, with the first plant (the 'plant') having a total capacity of c. 63,000 m3 of finished Accoya® output, expected to be operational in the course of 2016.

In return, Accsys will receive a series of licence payments, which have already commenced and will be made during the phased construction of the plant, and with royalty payments per volume of Accoya® produced thereafter.

The two companies have also signed an amendment to the licence agreement which now includes the possibility of Solvay constructing the plant in Arnhem on land Accsys currently owns, adjacent to the Company's existing manufacturing facility and in a phased manner. Solvay is now reviewing the two options for the optimal plant location, being either Arnhem, the Netherlands or Freiburg, Germany.

The decision on the plant and its location will be made by Solvay in the next few months.

In addition the two companies have agreed to examine the best ways to provide coordinated operational and maintenance services to both plants, and to review the best form of cooperation between the two companies going forward.

Further to the licence agreement becoming unconditional, Accsys and Solvay have entered a transitional phase in which Accsys will continue to sell to Accoya distributors in Solvay's region while working to transfer the relationships to Solvay.

Accoya sales and production

Revenue from sales of Accoya® increased by 74% to €20.2m in the nine months to December 2013 compared to the same nine month period in the previous year. Within this, sales to Accoya® customers (excluding sales to Medite) increased by 58% to €18.4m. Sales of Accoya to Medite resumed at the end of the previous financial year following a period in which Medite had built up initial stock levels, resulting in revenue of €1.9m (2012: nil).

This increasing demand for Accoya® continues to be seen across all regions and is attributable to both old and new distributors. We continue to see the benefit from our significant investment in sales and marketing over the last few years, for example the targeting of architectural audiences. In this respect we are pleased that the new calendar year has started very positively and we expect the trend of revenue growth to continue.

In November last year we reported that the Arnhem manufacturing plant was profitable at an EBITDA level. This has continued and gross margins are expected to improve further as we benefit from the economies of scale together with price increases which are being implemented in the first part of 2014.

Tricoya Technologies Limited

Tricoya Technologies Ltd ('TTL'), the INEOS and Accsys joint venture, continues to make progress in all areas including engineering, product development, marketing and business development.

The market evaluation of Medite Tricoya® continues to be positive with increasing acceptance of the product. TTL signed its first Tricoya® licence agreement with Medite in July 2013 which is conditional upon Medite obtaining approval from its Board of Directors.

Intellectual Property

During the period an Accoya® process patent was granted in Australia. Accsys' world-wide patent portfolio is expected to continue to grow as international patent applications enter their national and regional phases, and further applications are filed in both core and acetylation enabling technologies. The number of patent families is therefore anticipated to increase, adding to the depth and scope of the company's IP.

TTL is expected to continue to develop significant intellectual property that will reinforce the protection its business currently enjoys through a combination of registered and unregistered rights, further consolidating its patent holdings for products and processes.

Financial results

Total revenue for the nine months ended 31 December 2013 increased by 71% to €23.0m (2012: €13.4m). Total revenue included €1.9m of sales of Accoya to Medite to enable them to produce Medite Tricoya® and licence income of €0.5m.

The cash balance as at 31 December 2013 of €14.4m represents a decrease of €2.5m since 30 September 2013 and a decrease of €6.1m since 31 March 2013. The reduction included a cash outflow from operating activities (before changes in working capital) of €3.1m for the nine months ended 31 December 2013, which represents a 47% decrease compared to the corresponding nine month period in the previous year. An increase in working capital in the quarter ended 31 December 2013, largely attributable to the timing of raw material shipments, is expected to partially reverse over the next few months such that the cash balance at the financial year end is anticipated to be approximately €13m.

Diamond Wood

In August 2013, we took the decision to terminate our licence agreement with Diamond Wood as a result of Diamond Wood's failure to comply with their contractual obligations. Diamond Wood subsequently served a notice of arbitration challenging our position. We welcome the opportunity to confirm the validity of our termination and are extremely confident that the arbitration will be resolved in our favour. Whilst further details of the arbitration are subject to confidentiality, Accsys will provide a further update once the matter has been concluded.

Ends

For further information, please contact:

 

Accsys Technologies PLC

Paul Clegg, CEO

Hans Pauli, COO

Will Rudge, FD

 

 via Blythe Weigh Communications

Numis Securities

Nominated Adviser: Oliver Cardigan

Corporate Broking: Christopher Wilkinson

Ben Stoop

+44 (0) 20 7260 1000

 

Blythe Weigh Communications

 

Paul Weigh

Eleanor Parry

 

+44 (0) 20 7138 3204

+44 (0) 7989 129658

+44 (0) 7551 923620

 

Off the Grid (The Netherlands)

 

Frank Neervoort

Giedo Van Der Zwan

 

+31 681 734 236

+31 624 212 238

 

Notes to editors:

 

Accsys Technologies PLC(www.accsysplc.com) is an environmental science and technology company whose primary focus is on the production of Accoya® wood and technology licensing via its subsidiary, Titan Wood Limited, which has manufacturing operations in Arnhem, the Netherlands (through its subsidiary Titan Wood B.V.), a European office in Windsor, United Kingdom, and an American office in Dallas, Texas (via its subsidiary Titan Wood, Inc). All group subsidiaries are ultimately 100% owned by Accsys and trade as Accsys Technologies. Any references in this announcement to agreements with Accsys shall mean agreements with either Accsys or its subsidiary entities unless otherwise specified. Accsys Technologies PLC is listed on the London Stock Exchange AIM market and on Euronext Amsterdam by NYSE Euronext, under the symbols 'AXS'. Accsys' operations comprise three principal business units: (i) Accoya® wood production; (ii) technology development, focused on a programme of continuous development of and improvements to the process engineering and operating protocols for the acetylation of solid wood and the development of technology for the acetylation of wood elements; and (iii) the licensing of technology for the production of Accoya® wood and Tricoya® wood elements across the globe.

Accoya® wood (www.accoya.com) is produced using Accsys' proprietary patented acetylation technology, that effectively converts sustainably grown softwoods and non-durable hardwoods into what is best described as a "high technology wood". Distinguished by its durability, dimensional stability and, perhaps most importantly of all, its reliability (in terms of consistency of both supply and quality), Accoya® wood is particularly suited to exterior applications where performance and appearance are valued. Unlike most tropical and European hardwoods, its colour does not degrade when exposed to ultraviolet light. Moreover, the Accoya® wood production process does not compromise the wood's strength or machinability. The combination of UV resistance, dimensional stability, durability and retained strength means that Accoya® wood offers a wealth of new opportunities to architects, designers and specifiers. These benefits result in lower maintenance and total cost of ownership while using a higher sustainable and environmental responsible building material. For a full archive of Accoya® news, visit www.accoya.com/news.asp.

Tricoya® Wood Elements(www.tricoya.com) are produced using Accsys' proprietary technology for the acetylation of wood chips, and particles for use in the fabrication of wood based composites, including panel products. These composites demonstrate enhanced durability and dimensional stability which allow them to be used in a variety of applications that were once limited to solid wood or man-made products. Exploitation of Accsys' proprietary technology relating to Tricoya® Wood Elements is carried out through Tricoya Technologies Limited, a joint venture between Accsys and INEOS Industries Holdings Limited. Tricoya® Wood Elements are lauded as the first major innovation in the wood composites industry in more than 30 years.

Wood Acetylation is a process which increases the amount of 'acetyl' molecules in wood, thereby changing its physical properties. When carried out to a sufficient level throughout the wood, this process protects wood from rot by making it "inedible" to most micro-organisms and fungi, without - unlike conventional treatments - making it toxic. It also greatly reduces the wood's tendency to swell and shrink, making it less prone to cracking and ensuring that, when painted, it requires dramatically reduced maintenance.

 

 

Accsys Technologies is the trading name of Titan Wood Limited. ACCOYA®, TRICOYA® and the Trimarque Device are registered trademarks owned by Titan Wood Limited ("TWL"), a wholly owned subsidiary of Accsys Technologies PLC, and may not be used or reproduced without written permission from TWL, or in the case of the Tricoya® registered trademark, from Tricoya Technologies Limited, a joint venture between TWL and INEOS Industries Holdings Limited with exclusive rights to exploit the Tricoya® brand.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSTTMRTMBIBMTI
Date   Source Headline
8th Jun 202610:10 amRNS-RNotice of Results & Investor Presentation via IMC
21st Apr 20267:00 amRNSTrading Update
17th Apr 20267:00 amRNSAnalyst Site Visit, Arnhem, NL
7th Apr 202611:40 amRNSStandard form for notification of major holdings
30th Mar 20267:00 amRNSChange of external auditor
30th Jan 20261:30 pmRNSTotal Voting Rights
26th Jan 20267:00 amRNSStandard form for notification of major holdings
22nd Jan 20262:00 pmRNSStandard form for notification of major holdings
16th Jan 20267:00 amRNSAccsys Employee Share Plan - Issue of Shares
11th Dec 20252:00 pmRNSStandard form for notification of major holdings
11th Dec 20257:00 amRNS-RProgressive Research Initiation Note Publication
9th Dec 20254:06 pmRNSSecondary Sale in Accsys Technologies PLC Shares
25th Nov 20257:01 amRNS-RLaunch of Accsys Sustainability Plan
25th Nov 20257:00 amRNSInterim results for six months ended 30 Sep 2025
10th Nov 20257:00 amRNSNotice of Interim Results & Investor Presentation
22nd Oct 20257:00 amRNSSuccessful Completion of Debt Refinancing
24th Sep 20255:15 pmRNSResult of AGM
24th Sep 20257:00 amRNSTrading Update
21st Jul 202510:00 amRNS2025 Annual Report and Notice of AGM
14th Jul 20257:00 amRNSDirector/PDMR Shareholding
30th Jun 202512:30 pmRNSDirector/PDMR Shareholding
24th Jun 20257:00 amRNSPreliminary results for the year end 31 March 2025
5th Jun 20257:00 amRNS-RInvestor Presentation via Investor Meet Company
7th May 20257:00 amRNSTrading Update
2nd Apr 20257:00 amRNSAppointment of Nominated Advisor and Broker
27th Feb 20259:00 amRNSHolding(s) in Company
24th Feb 20259:00 amRNSHolding(s) in Company
24th Feb 20259:00 amRNSHolding(s) in Company
30th Jan 20257:00 amRNSInvestor Strategy Day
29th Nov 20249:00 amRNSDirector/PDMR Shareholding
27th Nov 20243:00 pmRNSDirector LTIP Award
26th Nov 20247:00 amRNSInterim results for six months ended 30 Sep 2024
6th Nov 20242:00 pmRNSNotice of Results
25th Sep 20243:00 pmRNSResult of AGM
24th Sep 20247:00 amRNSDirectorate Update
19th Sep 20247:00 amRNSHull Plant
4th Sep 20243:15 pmRNSDirector/PDMR Shareholding
4th Sep 20247:00 amRNSTrading Update
2nd Sep 20245:00 pmRNSTotal Voting Rights
2nd Sep 20245:00 pmRNSBlock listing 6 monthly return
16th Aug 20242:00 pmRNSNotice of Annual General Meeting 2024
19th Jul 20244:30 pmRNSAnnual Financial Report
19th Jul 20244:20 pmRNSDirector/PDMR Shareholding
5th Jul 20247:00 amRNSDirectorate Update
26th Jun 20247:00 amRNSPRELIMINARY RESULTS FOR THE YEAR END 31 MARCH 2024
16th May 20247:00 amRNSDirectorate Change
2nd May 20247:00 amRNSTrading Update
28th Mar 202412:00 pmRNSDirector Interests
1st Mar 20247:00 amRNSBlock listing Six Monthly return
27th Feb 20247:00 amRNSBlock listing application to AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.